Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03668613 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT03668613 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 84 participants.
The verdict
NCT03668613, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis. 84 subjects (most with moderate severity) were enrolled. Subjects were stratified by weight and disease severity.
Interventions
- DRUG secukinumab low dose
- DRUG secukinumab high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2018-08-29 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03668613
The ClinicalTrials.gov registry entry for NCT03668613 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which secukinumab low dose is the first listed.
NCT03668613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03668613 about?
NCT03668613 is a clinical study titled "Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis". This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis. 84 subjects (most with moderate severity) were enrolled. Subjects were stratified by weight and disease sev...
What is the current status of trial NCT03668613?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2018-08-29. Estimated completion is 2023-09-12.
What interventions are being tested in trial NCT03668613?
The interventions under investigation include: secukinumab low dose (DRUG), secukinumab high dose (DRUG).
Who is sponsoring clinical trial NCT03668613?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.